An open-label trial of quetiapine for antipsychotic-induced sexual dysfunction

Matthew J. Byerly, Emmeline Lescouflair, Mary T. Weber, Rhiannon M. Bugno, Robert Fisher, Thomas Carmody, Femina Varghese, A. John Rush

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

This study evaluated the effect of switching outpatients with schizophrenia and antipsychotic-induced sexual dysfunction to open-label quetiapine treatment. Secondary objectives were to compare the antipsychotic and prolactin-related effects of quetiapine versus prestudy antipsychotic treatment. Eight patients with at least moderately severe antipsychotic-induced sexual dysfunction (N = 7 taking risperidone, 4-6 mg/d; N = 1 taking haloperidol, 10 mg/d) were evaluated prospectively after they switched to 6 weeks of quetiapine treatment. The assessments that we used included evaluations of sexual functioning (Arizona Sexual Experience Scale [ASEX]; McGahuey et al., 2000), psychopathology (Positive and Negative Syndrome Scale [PANSS]; Kay, Fiszbeinm, & Opler, 1997), adverse events, and plasma prolactin levels. Quetiapine was associated with clinically and statistically significant improvement in ASEX total scores (p = 0.008) and significantly decreased PANSS total scores (p = 0.03). Plasma prolactin levels tended to decrease after the transition to quetiapine (p = 0.09). Quetiapine appears to offer an option to reduce antipsychotic-induced sexual dysfunction for outpatients with schizophrenia.

Original languageEnglish (US)
Pages (from-to)325-332
Number of pages8
JournalJournal of Sex and Marital Therapy
Volume30
Issue number5
DOIs
StatePublished - Oct 2004

Fingerprint

schizophrenia
Antipsychotic Agents
psychopathology
Prolactin
experience
event
Schizophrenia
Outpatients
evaluation
Risperidone
Haloperidol
Psychopathology
Quetiapine Fumarate
Therapeutics

ASJC Scopus subject areas

  • Social Sciences (miscellaneous)
  • Psychology(all)
  • Clinical Psychology

Cite this

Byerly, M. J., Lescouflair, E., Weber, M. T., Bugno, R. M., Fisher, R., Carmody, T., ... Rush, A. J. (2004). An open-label trial of quetiapine for antipsychotic-induced sexual dysfunction. Journal of Sex and Marital Therapy, 30(5), 325-332. https://doi.org/10.1080/00926230490465082

An open-label trial of quetiapine for antipsychotic-induced sexual dysfunction. / Byerly, Matthew J.; Lescouflair, Emmeline; Weber, Mary T.; Bugno, Rhiannon M.; Fisher, Robert; Carmody, Thomas; Varghese, Femina; Rush, A. John.

In: Journal of Sex and Marital Therapy, Vol. 30, No. 5, 10.2004, p. 325-332.

Research output: Contribution to journalArticle

Byerly, MJ, Lescouflair, E, Weber, MT, Bugno, RM, Fisher, R, Carmody, T, Varghese, F & Rush, AJ 2004, 'An open-label trial of quetiapine for antipsychotic-induced sexual dysfunction', Journal of Sex and Marital Therapy, vol. 30, no. 5, pp. 325-332. https://doi.org/10.1080/00926230490465082
Byerly, Matthew J. ; Lescouflair, Emmeline ; Weber, Mary T. ; Bugno, Rhiannon M. ; Fisher, Robert ; Carmody, Thomas ; Varghese, Femina ; Rush, A. John. / An open-label trial of quetiapine for antipsychotic-induced sexual dysfunction. In: Journal of Sex and Marital Therapy. 2004 ; Vol. 30, No. 5. pp. 325-332.
@article{5390792bc4e84fe5949d3b2292cd34c7,
title = "An open-label trial of quetiapine for antipsychotic-induced sexual dysfunction",
abstract = "This study evaluated the effect of switching outpatients with schizophrenia and antipsychotic-induced sexual dysfunction to open-label quetiapine treatment. Secondary objectives were to compare the antipsychotic and prolactin-related effects of quetiapine versus prestudy antipsychotic treatment. Eight patients with at least moderately severe antipsychotic-induced sexual dysfunction (N = 7 taking risperidone, 4-6 mg/d; N = 1 taking haloperidol, 10 mg/d) were evaluated prospectively after they switched to 6 weeks of quetiapine treatment. The assessments that we used included evaluations of sexual functioning (Arizona Sexual Experience Scale [ASEX]; McGahuey et al., 2000), psychopathology (Positive and Negative Syndrome Scale [PANSS]; Kay, Fiszbeinm, & Opler, 1997), adverse events, and plasma prolactin levels. Quetiapine was associated with clinically and statistically significant improvement in ASEX total scores (p = 0.008) and significantly decreased PANSS total scores (p = 0.03). Plasma prolactin levels tended to decrease after the transition to quetiapine (p = 0.09). Quetiapine appears to offer an option to reduce antipsychotic-induced sexual dysfunction for outpatients with schizophrenia.",
author = "Byerly, {Matthew J.} and Emmeline Lescouflair and Weber, {Mary T.} and Bugno, {Rhiannon M.} and Robert Fisher and Thomas Carmody and Femina Varghese and Rush, {A. John}",
year = "2004",
month = "10",
doi = "10.1080/00926230490465082",
language = "English (US)",
volume = "30",
pages = "325--332",
journal = "Journal of Sex and Marital Therapy",
issn = "0092-623X",
publisher = "Routledge",
number = "5",

}

TY - JOUR

T1 - An open-label trial of quetiapine for antipsychotic-induced sexual dysfunction

AU - Byerly, Matthew J.

AU - Lescouflair, Emmeline

AU - Weber, Mary T.

AU - Bugno, Rhiannon M.

AU - Fisher, Robert

AU - Carmody, Thomas

AU - Varghese, Femina

AU - Rush, A. John

PY - 2004/10

Y1 - 2004/10

N2 - This study evaluated the effect of switching outpatients with schizophrenia and antipsychotic-induced sexual dysfunction to open-label quetiapine treatment. Secondary objectives were to compare the antipsychotic and prolactin-related effects of quetiapine versus prestudy antipsychotic treatment. Eight patients with at least moderately severe antipsychotic-induced sexual dysfunction (N = 7 taking risperidone, 4-6 mg/d; N = 1 taking haloperidol, 10 mg/d) were evaluated prospectively after they switched to 6 weeks of quetiapine treatment. The assessments that we used included evaluations of sexual functioning (Arizona Sexual Experience Scale [ASEX]; McGahuey et al., 2000), psychopathology (Positive and Negative Syndrome Scale [PANSS]; Kay, Fiszbeinm, & Opler, 1997), adverse events, and plasma prolactin levels. Quetiapine was associated with clinically and statistically significant improvement in ASEX total scores (p = 0.008) and significantly decreased PANSS total scores (p = 0.03). Plasma prolactin levels tended to decrease after the transition to quetiapine (p = 0.09). Quetiapine appears to offer an option to reduce antipsychotic-induced sexual dysfunction for outpatients with schizophrenia.

AB - This study evaluated the effect of switching outpatients with schizophrenia and antipsychotic-induced sexual dysfunction to open-label quetiapine treatment. Secondary objectives were to compare the antipsychotic and prolactin-related effects of quetiapine versus prestudy antipsychotic treatment. Eight patients with at least moderately severe antipsychotic-induced sexual dysfunction (N = 7 taking risperidone, 4-6 mg/d; N = 1 taking haloperidol, 10 mg/d) were evaluated prospectively after they switched to 6 weeks of quetiapine treatment. The assessments that we used included evaluations of sexual functioning (Arizona Sexual Experience Scale [ASEX]; McGahuey et al., 2000), psychopathology (Positive and Negative Syndrome Scale [PANSS]; Kay, Fiszbeinm, & Opler, 1997), adverse events, and plasma prolactin levels. Quetiapine was associated with clinically and statistically significant improvement in ASEX total scores (p = 0.008) and significantly decreased PANSS total scores (p = 0.03). Plasma prolactin levels tended to decrease after the transition to quetiapine (p = 0.09). Quetiapine appears to offer an option to reduce antipsychotic-induced sexual dysfunction for outpatients with schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=4644344336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644344336&partnerID=8YFLogxK

U2 - 10.1080/00926230490465082

DO - 10.1080/00926230490465082

M3 - Article

C2 - 15672600

AN - SCOPUS:4644344336

VL - 30

SP - 325

EP - 332

JO - Journal of Sex and Marital Therapy

JF - Journal of Sex and Marital Therapy

SN - 0092-623X

IS - 5

ER -